eM-Patch temporarily and reversibly alters stratum corneum and epidermal water binding and retention to provide a means of managing the hydrophilic and lipophilic pathways.
An extract from one of OBJ's publications explaining our EM-Patch.
eM-Patch has field structures that work with body heat (thermodynamics) to open osmotic ( diffusion for one direction only ) shunts and appendageal pathways to provide faster onset, reduced lag time and greater control over dermal distribution.
The usual directionless diffusion in passive formulations gains direction by leading diamagnetic molecules faster and more effective through those shunts created by the patch. The size of those osmotic shunts is the secret to diversity of applications. As you rightly mentioned OBJ has conducted tests for Dipeptide Ala-Trp ( Alanine-Tryptophan ) of a molecular weight of 275.9. Dipeptide Ala-Trp is hydrophillic, meaining typically charged- polarized and hence ideal for our technology to be delivered through the skin regardless of its molecular weight.
OBJ's own research shows the enhancement of delivery of this dipeptide in a phosphate buffered saline solution under the influence of enhanced magnetic delivery.
These tests confirm OBJ's earlier results almost in an identical fashion.
Under the conditions tested, iontophoresis increased the in vitro permeability coefficient of ALA.HCl across human epidermis from 7 x 10−5 cm/h with passive diffusion to 110 x 10−5 cm/h with iontophoresis.
Compared with the numbers from the OBJ site listed above we can see that other researchers come to almost identical results. These overlapping test results confirming our own testing greatly support credibility of our technology and solidify my belief of successful outcomes with our partners worldwide.
As you mentioned nanotechnology, I would like to add another breakthrough in the making in that area which could benefit OBJ technology in the future tremendously.
UNC researchers have come close to synthesize blood. Traditionally earlier attempts failed as stiffening particles were cleansed out of the blood stream.
The secret to the new mimics lies in the flexibility of the product. The usual life span of a real blood cell is 120 days, by that time it had squeezed so often through microscopic pores inside the body that it naturally stiffens and eventually gets ejected out of the system. The new particle stays flexible longer and allows carrying the drugs inside it for prolonged periods of time allowing targeting cancer cells, for instance, more efficiently.
Given the successful application of a dipeptide as discussed above with our technology, the outlook to effectively transport nanoparticles of that size through the corneum stratum would open a whole new range of applications for the OBH technology.
Nanotechnolgy added to the mix of already ongoing discussions, evaluations, testing regimes of our technology will only diversify our formulations and hence the financial outlook of our company.
OBJ Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
(20min delay)